CA1168983A - Method and system for the controlled release of biologically active substances to a body fluid - Google Patents

Method and system for the controlled release of biologically active substances to a body fluid

Info

Publication number
CA1168983A
CA1168983A CA000356872A CA356872A CA1168983A CA 1168983 A CA1168983 A CA 1168983A CA 000356872 A CA000356872 A CA 000356872A CA 356872 A CA356872 A CA 356872A CA 1168983 A CA1168983 A CA 1168983A
Authority
CA
Canada
Prior art keywords
carbohydrate
conjugate
whenever prepared
obvious chemical
chemical equivalents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000356872A
Other languages
English (en)
French (fr)
Inventor
Michael Brownlee
Anthony Cerami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of CA1168983A publication Critical patent/CA1168983A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA000356872A 1979-07-31 1980-07-23 Method and system for the controlled release of biologically active substances to a body fluid Expired CA1168983A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US062,484 1979-07-31
US06/062,484 US4348387A (en) 1979-07-31 1979-07-31 Method and system for the controlled release of biologically active substances to a body fluid

Publications (1)

Publication Number Publication Date
CA1168983A true CA1168983A (en) 1984-06-12

Family

ID=22042805

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000356872A Expired CA1168983A (en) 1979-07-31 1980-07-23 Method and system for the controlled release of biologically active substances to a body fluid

Country Status (7)

Country Link
US (1) US4348387A (enExample)
EP (1) EP0032927B1 (enExample)
JP (1) JPH0413324B2 (enExample)
BR (1) BR8008775A (enExample)
CA (1) CA1168983A (enExample)
DE (1) DE3069598D1 (enExample)
WO (1) WO1981000354A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
AU733391B3 (en) * 1982-04-26 2001-05-10 American National Can Company Polymeric and film structure for use in heat shrinkable bags
EP0119650A3 (en) * 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1329761C (en) * 1988-07-25 1994-05-24 Vettai S. Ananthanarayanan Design of peptide hormones, chemotactic peptides and drug compounds
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CA2509382A1 (en) * 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
CN101027318B (zh) * 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
WO2007047997A2 (en) * 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
RU2011135730A (ru) 2009-01-28 2013-03-10 Смартселлз, Инк. Кристаллические инсулин-коньюгаты
JP2012516339A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 外因的刺激型制御放出物質体およびその使用
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088294A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugate based systems for controlled drug delivery
WO2010107520A1 (en) * 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
WO2012015691A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US11041009B2 (en) 2017-03-23 2021-06-22 Merck Sharp & Dohme Corp. Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
EP3586876A1 (en) * 2018-06-21 2020-01-01 Gubra ApS Glucose-sensitive peptide hormones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
DE2054446A1 (de) * 1970-11-05 1972-05-10 Henning, George Ernest von, 6800 Mannheim Biologische Reaktionskammer
US3857393A (en) * 1971-04-22 1974-12-31 Bio Response Inc Apparatus for use in the augmentation of the production of antibodies in animals and humans and the collection thereof
US3847890A (en) * 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
CA1040271A (en) * 1975-01-22 1978-10-10 Anthony M. Albisser Artificial beta cell

Also Published As

Publication number Publication date
EP0032927B1 (en) 1984-11-07
JPH0413324B2 (enExample) 1992-03-09
WO1981000354A1 (en) 1981-02-19
EP0032927A1 (en) 1981-08-05
EP0032927A4 (en) 1982-05-10
BR8008775A (pt) 1981-05-26
JPS56500965A (enExample) 1981-07-16
US4348387A (en) 1982-09-07
DE3069598D1 (en) 1984-12-13

Similar Documents

Publication Publication Date Title
US4348387A (en) Method and system for the controlled release of biologically active substances to a body fluid
US4469681A (en) Method and system for the controlled release of biologically active substances to a body fluid
Unger et al. The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs
Sakurai et al. Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs
Farraj et al. Nasal administration of insulin using bioadhesive microspheres as a delivery system
Hsueh et al. Regulation of luteinizing hormone receptors in testicular interstitial cells by gonadotropin
Brubaker et al. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2
Kim et al. Self-regulated glycosylated insulin delivery
Pardridge et al. Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier
US3847890A (en) Acidic monosaccharide-substituted proteins
Siegel et al. Mechanochemical approaches to self-regulating insulin pump design
EP0725648A1 (en) Hepatoselective pharmaceutical actives
Santeusanio et al. Suppressive effect of secretin upon pancreatic alpha cell function
JPS59501213A (ja) 生物学的活性物質用の結晶化炭水化物マトリックス、該マトリックスの製造方法、及びその使用
Singh et al. An insulin delivery system from oxidized cellulose
JPS6011426A (ja) 糖尿病患者を治療する際に有用なガラクトシル−インシユリン複合体
MARCO et al. Effect of endogenous intestinal glucagon-like immunoreactivity (GLI) on insulin secretion and glucose concentration in dogs
Wogensen et al. Interleukin-1 potentiates glucose stimulated insulin release in the isolated perfused pancreas
Lassmann-Vague et al. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps: metabolic consequences
CURRY et al. Dynamics of insulin release by perfused rat pancreases: effects of hypophysectomy, growth hormone, adrenocorticotropic hormone and hydrocortisone
Kim et al. Self regulating insulin delivery system—a chemical approach
Ohneda et al. Purification of canine gut glucagon-like immunoreactivity (GLI) and its insulin releasing activity
AU6129080A (en) Method and system for the controlled release of biologically active substances to a body fluid
Vagne et al. Effect of bombesin on gastric secretion and motility in the cat
Martin et al. Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep

Legal Events

Date Code Title Description
MKEX Expiry